Results 151 to 160 of about 3,549 (185)
Cancer Letters, 2016 Granulocyte colony-stimulating factor (G-CSF) is widely used for preventing neutropenia during chemotherapy. Polyethylene glycol-conjugated granulocyte colony-stimulating factor (PEG-G-CSF, pegfilgrastim) serves the same purpose but has a longer half ...
Ha-Reum Lee +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacokinetics of Pegfilgrastim
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003Pegfilgrastim is a granulocyte colony‐stimulating factor (G‐CSF) with a long half‐life and sustained duration of action. Pegfilgrastim is created with pegylation technology, whereby a 20‐kD polyethylene glycol moiety is conjugated to filgrastim (recombinant human G‐CSF), resulting in a larger molecule.
openaire +2 more sources
Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar
BioDrugs, 2019Pegfilgrastim-jmdb/MYL-1401H (FULPHILA™) [hereafter referred to as pegfilgrastim-jmdb] is a biosimilar of the reference pegylated recombinant granulocyte colony-stimulating factor pegfilgrastim. It is approved for use in patients receiving chemotherapy for malignancy to decrease the incidence of infection, as manifested by febrile neutropenia, in the ...
openaire +2 more sources